	US 12,312,636 B2
	*Nanovesicles derived from genus Bacillus* bacteria and use thereof**
Yoon-Keun Kim, Namyangju-si (KR)
Assigned to MD HEALTHCARE INC., Seoul (KR)
Appl. No. 16/325,023
Filed by MD HEALTHCARE INC., Seoul (KR)
PCT Filed Aug. 7, 2017, PCT No. PCT/KR2017/008497 § 371(c)(1), (2) Date Feb. 12, 2019, PCT Pub. No. WO2018/030732, PCT Pub. Date Feb. 15, 2018.
Claims priority of application No. 10-2016-0102650 (KR), filed on Aug. 12, 2016; and application No. 10-2017-0098860 (KR), filed on Aug. 4, 2017.
Prior Publication US 2019/0177783 A1, Jun. 13, 2019
Int. Cl. C12Q 1/6851 (2018.01); A23L 33/135 (2016.01); A61K 8/99 (2017.01); A61K 9/00 (2006.01); A61K 35/742 (2015.01); A61P 3/00 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01); A61Q 19/00 (2006.01); C12Q 1/6883 (2018.01); C12Q 1/6886 (2018.01); C12Q 1/689 (2018.01); A61K 35/00 (2006.01)

CPC C12Q 1/6851 (2013.01) [A23L 33/135 (2016.08); A61K 8/99 (2013.01); A61K 9/007 (2013.01); A61K 9/0073 (2013.01); A61K 35/742 (2013.01); A61P 3/00 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); A61P 37/00 (2018.01); A61Q 19/00 (2013.01); C12Q 1/6883 (2013.01); C12Q 1/6886 (2013.01); C12Q 1/689 (2013.01); A61K 2035/115 (2013.01); C12Q 2600/158 (2013.01); Y02A 50/30 (2018.01)]

7 Claims

1. A method for inhibiting IL-6 or TNF-α secretion caused by inflammation factors in a subject in need thereof, comprising: administering a composition consisting of an effective amount of vesicles from Bacillus subtilis as an active ingredient and a pharmaceutically acceptable carrier, to a subject with inflammation caused by inflammation factors, wherein the vesicles themselves are an active ingredient to inhibit secretion of IL-6 or TNF-α, and wherein the vesicles are naturally occurring vesicles secreted by Bacillus subtilis and the vesicles have a cell wall.